BusinessAxsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceBy Nasdaq OMXMar 27, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences ConferenceBy Nasdaq OMXMar 26, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics to Present at 17th Annual Needham Healthcare ConferenceBy Nasdaq OMXMar 19, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental NeurotherapeuticsBy Nasdaq OMXMar 12, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateBy Nasdaq OMXMar 7, 2018, 12:01 PM UTC
BusinessAxsome Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018By Nasdaq OMXFeb 28, 2018, 12:00 PM UTC
BusinessAxsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and DextromethorphanBy Nasdaq OMXFeb 26, 2018, 12:00 PM UTC
BusinessAxsome Therapeutics to Present at 2018 BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 5, 2018, 12:00 PM UTC
